CHYM reports its first earnings as a public company tonight, entering the print with a short position that has built sharply since listing — a tension set against a stock that has rallied 24% over the past month.
The short interest story is the clearest setup signal. Bears have added aggressively: the short position has grown 43% over the past 30 days, reaching 6.6% of the free float. That rate of accumulation is notable for a newly listed stock. Yet the borrow market tells a less alarming story — availability is extremely loose at roughly 993%, meaning lenders hold nearly ten times as many shares as are currently borrowed, and the cost to borrow is just 0.43%. Short sellers are building positions, but they face no squeeze pressure whatsoever. Options positioning is mildly cautious — the put/call ratio is running slightly above its 20-day average at 0.53 — but the z-score of 0.88 places it well within a normal range, well short of any genuine defensive signal. The stock closed at $25.92 on Wednesday, up 3.9% on the day and 15.6% over the past week, outpacing peers AFRM (+7.9% on the week) and TOST (+4.5%), though well behind , which surged 30.6%.
The bull and bear debate for Chime turns on the durability of its growth metrics and the risks embedded in its credit model. Bulls point to strong engagement trends — average revenue per active member hit $245 in the most recent quarter, up 6% year-over-year — and platform revenue growing at a 90% average rate over the past four quarters, driven by the MyPay product. Adjusted EBITDA margins expanded nearly 900 basis points to 5.3%, suggesting the unit economics are improving. Analyst coverage has been broadly constructive since the IPO: Barclays initiated with Overweight in early July at a $26 target, and Canaccord Genuity has held a $40 Buy through recent volatility, though BMO trimmed its target to $28 from $30 later in the month while keeping an Outperform. The consensus mean target of $30.10 implies meaningful upside from the current price. Bears counter with a more structural concern: that Chime's risk model is unproven in a deteriorating macro environment, that credit losses could accelerate, and that altered pricing agreements with card networks or a more competitive fintech landscape could erode the payments revenue underpinning that growth.
Insider activity adds a layer of caution. The CEO, CFO, President, and General Counsel all sold shares in May at prices around $17.88 — well below where the stock now trades. Those sales were small in dollar terms and typical of post-IPO lockup activity, but the pattern is consistent selling rather than any sign of internal conviction at current levels. The top institutional holders — DST Global, CrossLink Capital, and General Atlantic — are large legacy venture backers with no reported changes, and Vanguard entered in the first quarter, adding fresh institutional credibility.
The one comparable earnings reaction on record offers a sobering data point: CHYM fell 8.2% the day after its June 2 report and extended that loss to 11.2% over the following five days. Tonight's print is therefore less a test of whether Chime can grow and more a test of whether it can sustain the margin trajectory and membership trends that justify a stock trading nearly 50% above its prior post-earnings level.
See the live data behind this article on ORTEX.
Open CHYM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
